TextbookPsychiatry & Mental HealthObsessive-Compulsive Disorder

Obsessive-Compulsive Disorder

OCD is characterised by recurrent obsessions (intrusive thoughts) and/or compulsions (repetitive behaviours) causing significant distress. Lifetime prevalence is approximately 2-3%.

Key Facts

  • Obsessions are recurrent, unwanted intrusive thoughts, images, or urges that cause marked anxiety
  • Compulsions are repetitive behaviours or mental acts performed to reduce anxiety caused by obsessions
  • Lifetime prevalence ~2-3%; equal sex ratio; bimodal onset (childhood/early adulthood)
  • First-line treatment: CBT with exposure and response prevention (ERP) ± SSRI (NICE CG31)
  • SSRI doses for OCD are typically higher than for depression (e.g., fluoxetine 60-80mg, sertraline 200mg)
  • Clomipramine (TCA) is the most effective single agent for OCD but has more side effects - second-line
  • Y-BOCS (Yale-Brown Obsessive Compulsive Scale) is the gold standard severity measure
  • Common themes: Contamination/washing, harm/checking, symmetry/ordering, forbidden thoughts (religious, sexual, aggressive)

Overview

Key Facts

OCD is a chronic neuropsychiatric disorder characterised by obsessions and compulsions that are time-consuming, distressing, and functionally impairing. It is one of the most disabling psychiatric conditions.

Epidemiology

Lifetime prevalence is 2-3%. Equal sex distribution overall, but males have earlier onset. Mean age of onset is 19-20 years (bimodal: childhood peak ~10 years, adult peak ~21 years). Average delay to treatment is 7-10 years. OCD accounts for significant disability - ranked by WHO as one of the top 10 most disabling conditions.

Aetiology

  • Genetic: Heritability ~40-50%; first-degree relatives have 4× increased risk
  • Neuroanatomical: Cortico-striato-thalamo-cortical (CSTC) circuit dysfunction - orbitofrontal cortex and caudate nucleus hyperactivity
  • Serotonergic: Serotonin dysfunction - basis for SSRI treatment
  • Autoimmune: PANDAS (Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections) - abrupt OCD onset post-streptococcal infection in children
  • Psychological: Inflated responsibility beliefs, thought-action fusion, intolerance of uncertainty

Pathophysiology

  • CSTC circuit model: Overactivity in orbitofrontal cortex → excessive error signalling → "something is wrong" feeling → compulsive behaviour to reduce anxiety
  • Serotonin hypothesis: Supported by selective response to serotonergic drugs (SSRIs, clomipramine) but not noradrenergic drugs
  • Glutamate dysfunction: Emerging evidence - riluzole and memantine under investigation
  • ERP mechanism: Habituation - repeated exposure to anxiety-provoking stimuli without performing compulsion leads to anxiety reduction over time

Clinical Presentation

Common Obsession Themes

  • Contamination: Fear of germs, dirt, bodily fluids → washing/cleaning compulsions
  • Harm: Fear of causing harm to self or others → checking compulsions
  • Symmetry/ordering: Need for things to be "just right" → arranging, counting
  • Forbidden thoughts: Intrusive sexual, religious, or aggressive thoughts → mental rituals, reassurance-seeking

Common Compulsion Types

  • Washing and cleaning
  • Checking (locks, appliances, safety)
  • Counting, ordering, arranging
  • Mental rituals (praying, repeating words)
  • Reassurance-seeking
  • Hoarding (may overlap with hoarding disorder)

Key Clinical Features

  • Patient recognises thoughts are their own (not inserted) and usually recognises they are excessive/irrational
  • Attempts to resist compulsions cause mounting anxiety
  • Symptoms are time-consuming (>1 hour/day) and cause significant distress or functional impairment

Red Flags

  • Severe OCD with total functional impairment - consider specialist inpatient OCD unit
  • OCD with psychotic features - poor insight subtype, consider antipsychotic augmentation
  • Sudden onset OCD in child post-streptococcal infection - PANDAS, consider paediatric referral
  • Suicidal ideation - comprehensive risk assessment

Differential Diagnosis

DiagnosisKey FeaturesInvestigation
GADExcessive worry about real-life concerns (not ego-dystonic)GAD-7, clinical assessment
Body dysmorphic disorderPreoccupation with perceived physical defectClinical assessment
Illness anxiety disorderPreoccupation with having serious illnessClinical assessment
Tic disorder/Tourette'sMotor/vocal tics; may coexist with OCDClinical observation
Psychotic disorderDelusions (ego-syntonic, not resisted)MSE, psychiatric assessment
Autism spectrum disorderRigid routines and rituals, but not distressingDevelopmental history, ADOS
Anankastic personality disorderPervasive perfectionism, rigidity - ego-syntonicPersonality assessment

Diagnosis / Investigation

Bedside

  • Y-BOCS: Gold standard severity rating (0-40); mild <16, moderate 16-23, severe 24-31, extreme 32-40
  • OCI-R (Obsessive-Compulsive Inventory-Revised): Self-report screening tool
  • PHQ-9/GAD-7: Screen for comorbid depression and anxiety
  • Risk assessment: Suicidal ideation, self-harm

Bloods

  • TFTs: Exclude thyroid dysfunction
  • FBC: Baseline if starting clomipramine
  • ASOT/anti-DNase B: If PANDAS suspected in children

Special Tests

  • ECG: Before clomipramine (cardiotoxic); baseline for SSRIs at high doses
  • Neuropsychological testing: If cognitive concerns or diagnostic uncertainty
  • Neuroimaging: Not routine - research shows OFC and caudate hyperactivity on fMRI

Management

Non-pharmacological

  • Mild OCD: Low-intensity CBT (guided self-help with ERP)
  • Moderate-severe OCD: High-intensity CBT with ERP (specialist therapist, 12-20 sessions)
  • ERP protocol: Graded exposure to feared stimuli + prevention of compulsive response → habituation
  • Family involvement: Psychoeducation, reducing accommodation of compulsions

Pharmacological (NICE CG31)

  • First-line SSRI (higher doses than for depression):
    • Fluoxetine 60-80mg OD
    • Sertraline 200mg OD
    • Fluvoxamine 100-300mg OD
    • Paroxetine 40-60mg OD
  • Allow 8-12 weeks at adequate dose before concluding ineffective (longer than depression)
  • Second-line: Clomipramine 75-250mg OD (most effective single agent, but anticholinergic/cardiac side effects)
  • Augmentation (specialist): Low-dose antipsychotic (risperidone 0.25-2mg, aripiprazole 5-15mg) added to SSRI
  • Treatment duration: Continue for ≥12 months after remission; gradual tapering

Referral Criteria

  • Moderate-severe OCD - secondary care for CBT with ERP and SSRI optimisation
  • Treatment-resistant OCD (failed 2 SSRI trials + CBT) - specialist OCD service
  • Severe functional impairment - specialist/inpatient OCD unit
  • PANDAS - paediatric neurology/psychiatry

Prognosis

  • CBT with ERP: 60-70% response rate; gains well-maintained with continued practice
  • SSRIs: 40-60% response rate; high relapse rate on discontinuation (~50%)
  • Combined CBT + SSRI: Best outcomes, especially for moderate-severe OCD
  • Course: Chronic and relapsing in most cases; ~20% have a chronic unremitting course
  • Predictors of poor outcome: Early onset, poor insight, hoarding symptoms, comorbid depression, family history
  • Functional recovery: Even with symptom reduction, many patients have residual functional impairment

Other Relevant Information

Y-BOCS Severity

ScoreSeverity
0-7Subclinical
8-15Mild
16-23Moderate
24-31Severe
32-40Extreme

NICE CG31 Stepped Care

StepSeverityIntervention
1MildGuided self-help with ERP (6-8 weeks)
2Mild (failed step 1)Brief CBT with ERP or SSRI
3ModerateCBT with ERP (including ERP) + SSRI
4Severe/treatment-resistantSpecialist OCD unit, clomipramine, augmentation, consider neurosurgery (last resort)